



Universiteit  
Leiden  
The Netherlands

## **Migraine as a cardiovascular risk factor for women**

Linstra, K.M.

### **Citation**


Linstra, K. M. (2023, May 16). *Migraine as a cardiovascular risk factor for women*. Retrieved from <https://hdl.handle.net/1887/3618277>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3618277>

**Note:** To cite this publication please use the final published version (if applicable).



# APPENDICES

## SUPPLEMENTARY MATERIAL: CHAPTER 3

### 1. LUMINA BACKGROUND INFORMATION

Dutch migraine patients aged 18–80 years were recruited via nationwide public announcement, advertising in lay press and our research website ([www.lumc.nl/hoofdpijn](http://www.lumc.nl/hoofdpijn)). They were considered eligible after a two-step inclusion process using validated questionnaires via the dedicated Leiden University Migraine Neuro-Analysis (LUMINA) website. Additionally, patients attending our outpatient headache clinic were invited to participate by a letter. Patients were first asked to fill out a validated web-based screening questionnaire with a sensitivity of 0.93 and specificity of 0.36.<sup>1</sup> Patients who fulfilled the screening criteria, were sent a validated web-based extended migraine questionnaire<sup>2</sup>, based on the International Classification of Headache Disorders criteria (previously ICHD-2, now ICHD-3 version) criteria.<sup>3</sup> The specificity of the second questionnaire was 0.95 and sensitivity was 0.45.<sup>2</sup> This questionnaire is accessible for patients via our research website and is described in English in detail by van Oosterhout et al. 2011.<sup>2</sup> We consider the cohort a well-defined web-based cohort. Four percent of subjects were included from our headache outpatient clinic and 87% of the participants were previously diagnosed with migraine by a physician. In addition to questions that were necessary to diagnose migraine accurately, the extended questionnaire also included items on demographic factors, aura and headache characteristics, acute and prophylactic headache medication use, and allodynia. Healthy controls were free of any known neurological or psychiatric disorders and did not have any primary or secondary headaches apart from an occasional episodic tension type headache. Participants unable to use the web-based questionnaires due to lack of the needed internet skills were allowed to fill out the questionnaires on paper.

### 2. QUESTIONNAIRES AND RATING ON THERMAL DISCOMFORT AND COLD EXTREMITIES (TDCE) AND DIFFICULTIES INITIATING SLEEP (DIS)

To accommodate the participants of this research, the following questionnaires were translated to Dutch. Questionnaire and rating are adapted from Kräuchi et al.<sup>4</sup>

#### **Thermal Discomfort and Cold Extremities (TDCE)**

In order to calculate a score, the following two questions were asked:

(A) During the past month, how intensely did you suffer from cold hands?

Answer categories were: 1='not at all', 2='a little', 3='quite', 4='extraordinary'.

(B) During the past month, how intensely did you suffer from cold feet?

Answer categories were: 1='not at all', 2='a little', 3='quite', 4='extraordinary'.

For categorical analyses TDCE was rated as relevant when the answer to question A or the answer to question B was option 3 or 4.

#### **Difficulties Initiating Sleep (DIS)**

(A) During the past month, how often was your sleep onset latency (SOL) longer than 30 min?

Answer categories were: 1='never', 2='seldom', 3='1–2 times per week', 4='≥3 times per week'.

(B) During the past month, how long (in minutes) has it usually taken to fall asleep?

Answer: ... minutes

(C) During the past month, was it a problem for you to fall asleep?

Answer categories were: 1='not at all', 2='a little', 3='quite', 4='extraordinary'.

For categorical analyses, DIS was categorized as relevant when the answer to question A was option 3 or 4 and the answer of question C was option 3 or 4.

## REFERENCES

- 1 Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. *Neurology*. 1999;53:537–42.
- 2 van Oosterhout WPJ, Weller CM, Stam AH, et al. Validation of the web-based LUMINA questionnaire for recruiting large cohorts of migraineurs. *Cephalgia*. 2011;31:1359–67.
- 3 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. *Cephalgia*. 2018;38:1–211.
- 4 Kräuchi K, Gasio PF, Vollenweider S, Von Arb M, Dubler B, Orgül S, Flammer J, Stutz EZ. Cold extremities and difficulties initiating sleep: evidence of co-morbidity from a random sample of a Swiss urban population. *J Sleep Res*. 2008;17:420–6.

## SUPPLEMENTARY MATERIAL: CHAPTER 4

See Supplementary material: Chapter 3, 1. LUMINA background information.

## SUPPLEMENTARY MATERIAL: CHAPTER 5

**Supplemental Table 1.** Additional general, cardiometabolic, gynaecological/obstetric and endocrine characteristics of the total study population, that includes women with and without migraine who were diagnosed with PCOS.

	<b>All subjects (N = 49)</b>	<b>Women with migraine (N = 23)</b>	<b>Women without migraine (N = 26)</b>	<b>P-value</b>
General parameters and intoxications <sup>1</sup>				
Education				0.128
Pre-vocational secondary	9 (18.4%)	5 (21.7%)	4 (15.4%)	
Secondary vocational	10 (20.4%)	2 (8.7%)	8 (30.8%)	
Senior general secondary/ Pre-university	5 (10.2%)	3 (13.0%)	2 (7.7%)	
Higher professional	18 (36.7%)	7 (30.4%)	11 (42.3%)	
University/ PhD/ Postdoc	6 (12.2%)	5 (21.7%)	1 (3.8%)	
Unknown	1 (2.0%)	1 (4.3%)	0 (0%)	
Alcohol use of consumers (units/week)	1.0 (0.3–3.8)	1.3 (0.3–5.0)	0.8 (0.1–1.5)	0.415
Practitioner of a sport <sup>2</sup>	21 (43.8%)	6 (27.3%)	15 (57.7%)	0.045*
Anthropometrics				
Waist (cm)	98.0 (87.3–108.3)	95.0 (86.0–109.0)	100.0 (92.3–109.0)	0.312
Hip (cm)	112.0 (104.0–121.0)	109.0 (101.5–116.3)	116.5 (107.8–123.0)	0.055
Cardiometabolic parameters				
Non-fasting glucose (mmol/L) <sup>3</sup>	5.0 (4.0–5.7)	5.0 (4.0–5.5)	4.9 (4.0–6.6)	0.923
Total cholesterol (mmol/L) <sup>3</sup>	5.2 (4.4–6.1)	5.3 (4.5–6.0)	5.1 (4.4–6.4)	0.886
HDL cholesterol (mmol/L) <sup>3</sup>	1.5 (0.4)	1.5 (0.3)	1.5 (0.4)	0.942
Total cholesterol to HDL ratio <sup>3</sup>	3.6 (2.9–4.6)	3.7 (2.7–4.5)	3.5 (3.1–4.7)	0.728
LDL cholesterol (mmol/L) <sup>3</sup>	3.1 (1.0)	3.0 (1.0)	3.2 (1.0)	0.575
Triglycerides (mmol/L) <sup>3</sup>	1.2 (0.8–1.8)	1.0 (0.7–1.8)	1.3 (1.0–1.9)	0.356
ApoA1 (g/L) <sup>3</sup>	1.8 (0.4)	1.7 (0.3)	1.8 (0.5)	0.393
ApoB (g/L) <sup>3</sup>	0.8 (0.7–1.0)	0.8 (0.7–1.0)	0.8 (0.7–1.0)	0.854
Lp(a) (g/L) <sup>3</sup>	0.09 (0.05–0.2)	0.07 (0.04–0.2)	0.10 (0.06–0.2)	0.623
Gynaecological/obstetric parameters				
Age at menarche (years) <sup>4</sup>	13.0 (12.0–14.0)	13.0 (12.0–14.0)	13.5 (12.3–15.0)	0.093
Number of pregnancies in total	2.0 (1.0–3.0)	2.0 (1.0–4.0)	2.0 (1.0–3.0)	0.310
Number of pregnancies that lasted at least 6 months	2.0 (1.0–2.0)	2.0 (1.0–2.0)	2.0 (1.0–2.0)	0.763

■ **Supplemental Table 1.** Continued

	<b>All subjects (N = 49)</b>	<b>Women with migraine (N = 23)</b>	<b>Women without migraine (N = 26)</b>	<b>P-value</b>
Endocrine parameters <sup>2</sup>				
LH (U/L)	6.4 (1.8–25.4)	3.1 (1.3–17.9)	11.1 (2.0–25.9)	0.230
FSH (U/L)	8.7 (3.4–38.6)	6.7 (2.7–23.6)	11.6 (3.8–42.6)	0.243
AMH (µg/L) <sup>5</sup>	0.1 (0.01–0.7)	0.08 (0.01–0.7)	0.1 (0.01–0.8)	0.913
Androstenedione (nmol/L)	2.2 (1.6–3.7)	2.2 (1.6–4.1)	2.1 (1.6–2.9)	0.515
DHEA (nmol/L) <sup>6</sup>	8.5 (5.4–11.2)	9.1 (5.1–11.6)	8.3 (5.4–11.0)	0.723
DHEA sulfate (µmol/L)	2.7 (1.3)	2.7 (1.2)	2.6 (1.4)	0.682

Values of all subjects are displayed as means (standard deviation) or medians (interquartile range,  $Q_3 - Q_1$ ), or as numbers (percentage). Differences between participants with and without migraine were tested with Student's T-test for variables with a normal distribution, while the Mann-Whitney U test was used for variables with a skewed distribution and for variables with a non-normal distribution in one group. The Fisher's exact test was used for categorical data.

Abbreviations: AMH, Anti-Müllerian hormone; DHEA, dehydroepiandrosterone; FSH, follicle-stimulating hormone; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LH, luteinizing hormone

<sup>1</sup> Self-reported; <sup>2</sup> Data are missing in one migraine patient, that has been excluded from the analyses; <sup>3</sup> Data are missing in one patient without migraine, that has been excluded from the analyses; <sup>4</sup> Data are missing in two patients without migraine, that have been excluded from the analyses; <sup>5</sup> Hormone levels below the detection limit have been considered to be at the detection limit, which is 0.01. This was the case in 6 migraine patients and 8 patients without migraine; <sup>6</sup> Hormone levels below the detection limit have been considered to be at the detection limit, which is 3.6. This was the case in 1 migraine patient and 3 patients without migraine.

## SUPPLEMENTAL ANALYSES

### CARDIOVASCULAR RISK SCORE IN RELATION TO LTH MEASUREMENTS AND ENDOPAT MEASUREMENTS

Furthermore, we examined the correlation between the FRS and outcome measures of the EndoPAT in 42 participants, including 21 migraine patients. We observed no relation between the natural log-transformed FRS (lnFRS) and the lnRHI scores (Pearson's  $r = 0.17$  (95% CI [-0.14–0.45];  $p = 0.279$  and  $R^2 = 0.03$ ). Similarly, no correlation was found between the lnFRS and the AI@75 (Pearson's  $r = 0.14$  (95% CI [-0.17–0.43];  $p = 0.375$  and  $R^2 = 0.02$ ). Further stratification according to the migraine diagnosis did not result in any significant correlations between the lnFRS and the (transformed) lnRHI or AI@75 scores either (data not shown).

Lastly, we examined associations between the FRS and LTH measurements in 47 participants. To capture the total effect of the LTH response, without blockade of any underlying mechanism, we studied the AUC of the entire LTH response, corrected for its baseline, under control conditions.

No association was found between the lnFRS and the natural log-transformed AUC of the total LTH response under control conditions in all participants (Pearson's  $r = -0.12$  (95% CI [-0.40–0.17];  $p = 0.415$  and  $R^2 = 0.01$ ). Further stratification according to the migraine diagnosis did not result in any significant correlations in patients with or without migraine either (data not shown).

## SUPPLEMENTARY MATERIAL: CHAPTER 6

### ANALYSES OF BASELINE CHARACTERISTICS AMONG MIGRAINEURS VS NON-MIGRAINEURS

Migraine diagnosis was established using the Migraine for Stroke Screener (MISS). See supplementary material: chapter 7.

■ **Table 1.** migraine vs no migraine

	<b>Migraine (n=46)</b>	<b>No migraine (n=107)</b>	<b>P-value</b>
Age at event; median (IQR)	59.0 (18.3)	68.0 (19.5)	0.00
BMI; median (IQR)	26.0 (7.4)	26.1 (6.6)	0.82
Penumbra surface; median (IQR)	12184 (12440)	10021 (14726)	0.65
Infarct core; median (IQR)	1405 (3276)	2207 (6487)	0.39
Penumbra/infarct core index; median (IQR)	0.9 (0.2)	0.8 (0.4)	0.56
Infarctvolume; median (IQR)	10.9 (44.6)	16.6 (36.0)	0.84
Toast classification			0.93
Large vessel disease	14 (30)	26 (24)	
Small vessel / lacunar infarct	7 (15)	19 (18)	
Cardial embolic	8 (17)	20 (19)	
Dissection	3 (7)	1 (1)	
Other/unknown	16 (35)	39 (36)	
mRS, pre-admission $\geq 2$	2 (4)	9 (10)	0.51
mRS, 3 months FU $\geq 2$	20 (43)	50 (47)	0.64
NIHSS $\geq 5$	22 (48)	63 (59)	0.21
EQ5D $\geq 6$	28 (61)	71 (66)	0.86
BI $\leq 17$	2 (4)	11 (10)	0.35

Data are expressed as n (%) unless otherwise stated



## SUPPLEMENTARY MATERIAL: CHAPTER 7

### **MIGRAINE SCREENER FOR STROKE (MISS) QUESTIONNAIRE**

Migraine Screener for Stroke (MISS) is a 5 question reliable screening tool for migraine diagnosis in patients with transient ischemic attack or stroke. The screener was validated through semi-structured telephone interviews with the International Classification of Headache Disorders, second-edition criteria as gold standard. The sensitivity of all questions combined was 0.47 (95% CI 0.31-0.62), the specificity was 0.97 (95% CI 0.93-0.99), the positive predictive value (PPV) was 0.80 (95% CI 0.59-0.93) and the negative predictive value (NPV) was 0.87 (95% CI 0.82-0.92). For assessing migraine with aura, the question about visual disturbances had a good NPV (0.99, 95% CI 0.96-1.00), but a low PPV (0.38, 95% CI 0.24-0.53). To prevent misclassification, especially for the aura symptoms, patients with a positive screener should be interviewed more extensively to confirm the migraine diagnosis.<sup>1</sup>

---

*Question 1. Have you ever had a migraine attack or do you still have migraine attacks?*

Never  
1-4 times  
≥5 times  
Unknown

---

*Question 2. Have you ever been diagnosed with migraine by a physician?*

Yes  
No  
Unknown

---

*Question 3. Have you ever had severe headache attacks accompanied by nausea or vomiting?*

Never  
1-4 times  
≥5 times  
Unknown

---

*Question 4. Have you ever had severe headache attacks accompanied by hypersensitivity to lights and sounds?*

Never  
1-4 times  
≥5 times  
Unknown

---

*Question 5. Have you ever had visual disturbances lasting 5-60 min followed by headache?*

Never  
1-2 times  
≥3 times  
Unknown

---

**Table 3. a** Screener versus final ICHD-II diagnosis of migraine as gold standard

Screener question	Answer to screener question	Final diagnosis		Test characteristics (95% CI)
		migraine	no migraine	
(1) Self-reported migraine	Yes, ever (n)	43	19	PPV 0.69 (0.57–0.82) NPV 0.97 (0.93–0.99)
	No, never (n)	5	149	
		Sens 0.90 (0.77–0.97)	Spec 0.89 (0.84–0.94)	
(2) Diagnosed with migraine by a physician	Yes, ever (n)	26	8	PPV 0.76 (0.59–0.89) NPV 0.89 (0.84–0.94)
	No, never (n)	20	160	
		Sens 0.57 (0.41–0.71)	Spec 0.95 (0.91–0.98)	
(3) Severe headache with nausea	Yes, ever (n)	42	17	PPV 0.71 (0.58–0.82) NPV 0.97 (0.93–0.99)
	No, never (n)	5	148	
		Sens 0.89 (0.77–0.97)	Spec 0.90 (0.85–0.94)	
(4) Severe headache accompanied by hypersensitivity to light and sound	Yes, ever (n)	44	18	PPV 0.71 (0.58–0.82) NPV 0.99 (0.95–1.00)
	No, never (n)	2	149	
		Sens 0.96 (0.85–1.00)	Spec 0.89 (0.85–0.94)	
(5) Visual disturbances followed by headache	Yes, ever (n)	28	20	PPV 0.58 (0.43–0.72) NPV 0.91 (0.85–0.95)
	No, never (n)	15	144	
		Sens 0.65 (0.49–0.79)	Spec 0.88 (0.83–0.93)	
All questions combined	Yes, ever (n)	20	5	PPV 0.80 (0.59–0.93) NPV 0.87 (0.82–0.92)
	No, never (n)	23	156	
		Sens 0.47 (0.31–0.62)	Spec 0.97 (0.93–0.99)	

Sens = Sensitivity; Spec = specificity; missing data <5%.

**b** Visual disturbances followed by headache versus final ICHD-II diagnosis of migraine with aura as gold standard

Screener question	Answer to screener question	Final diagnosis		Test characteristics (95% CI)
		migraine with aura	no migraine with aura	
(5) Visual disturbances followed by headache	Yes, ever (n)	18	30	PPV 0.38 (0.24–0.53) NPV 0.99 (0.96–1.00)
	No, never (n)	2	157	
		Sens 0.90 (0.68–0.99)	Spec 0.90 (0.68–0.99)	

Sens = Sensitivity; Spec = specificity; missing data <7%.

- van der Willik D, Pelzer N, Algra A, Terwindt GM, Wermer MJH. Assessment of Migraine History in Patients with a Transient Ischemic Attack or Stroke; Validation of a Migraine Screener for Stroke. *Eur Neurol.* 2017;77(1-2):16-22.

## SUPPLEMENTARY MATERIAL: CHAPTER 8

### SEE SUPPLEMENTARY MATERIAL: CHAPTER 7: MISS QUESTIONNAIRE.

In the present study, migraine diagnosis was considered positive when participants answered confirmatively to a combination of the three questions selected to obtain the highest possible predictive value (ever migraine attack, ever severe headache with nausea/vomiting or ever severe headache with photo- and/or photophobia, positive predictive value: 0.80 (0.66–0.90) negative predictive value: 0.96 (0.91–0.98))<sup>5</sup> or in case of migraine diagnosis by physician's report.

## ABBREVIATIONS

ACOG	american congress of obstetricians and gynecologists
ADMA	asymmetric dimethylarginine
ASCO	atherosclerosis small-vessel disease cardiac pathology other causes
ATC	anatomical therapeutic chemical
AUC	area under curve
BMI	body mass index
BP	blood pressure
CADASIL	cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
CI	confidence interval
CGRP	calcitonin gene related peptide
CSD	cortical spreading depolarization
CVD	cardiovascular disease
COC	combined oral contraceptives
COX-1	cyclooxygenase-1
CREW	cardiovascular healthy aging in women
CREW-MIST	cardiovascular healthy aging in women microvascular status
CT	computed tomography
DBF	dermal blood flow
DM	diabetes mellitus
DIS	difficulty initiating sleep
DUST	dutch acute stroke study
EDHF	endothelium derived hyperpolarizing factor
EMLA	eutectic mixture of local anesthetics
EPC	endothelial precursor cells
ET-1	endothelin-1
FAI	free androgen index
FHM	familial hemiplegic migraine
FMD	flow mediated dilation
FRS	framingham risk score
GABA	gamma-aminobutyric acid
GWAS	genome wide association study
HDL	high density lipoprotein
IHR	hazard ratio
HRT	hormone replacement therapy
ICD	international classification of diseases
ICHD	international classification of headache disorders
ICPC	international classification of primary care
IHS	international headache society
LAA	large artery atherosclerosis
LACI	lacunar infarct

LH	luteinizing hormone
LTH	local thermal hyperaemia
LNMA	ng-monomethyl-L-arginine
LUMINA	leiden university migraine neuro-analysis
MA	migraine with aura
MI	myocardial infarction
MISS	migraine screener for stroke
MO	migraine without aura
MRI	magnetic resonance imaging
MRM	menstrually related migraine
mRS	modified rankin scale
NIHSS	national institutes of health stroke scale
NO	nitric oxide
NPRS	numeric pain rating scale
OCP	oral contraceptives
OR	odds ratio
PACAP	pituitary adenylate cyclase activating peptide
PACI	partial anterior circulation infarct
PE	preeclampsia
PCOS	polycystic ovary syndrome
PFO	patent foramen ovale
POCI	posterior circulation infarct
PSI-CVA	parelsoer institute cerebrovascular accident initiative
PVD	peripheral vessel disease
RR	relative risk
RHI	reactive hyperaemia index
RVCL-S	retinal vasculopathy with cerebral leukodystrophy and systemic manifestations
SHBG	sex hormone-binding globulin
STIZON	stichting informatievoorziening voor zorg en onderzoek
SVD	small vessel disease
TACI	total anterior circulation infarct
TIA	transient ischemic attack
TDCE	thermal discomfort and cold extremities
TOAST	trial of org 10172 in acute stroke treatment
TRPV-1	transient receptor potential vanilloid 1
WHO	world health organization
WML	white matter lesions

## LIST OF PUBLICATIONS

**Linstra KM**, Ibrahim K, Terwindt GM, Wermer MJH, MaassenVanDenBrink A. Migraine and cardiovascular disease in women. *Maturitas*. 2017;97:28-31

**Linstra KM**, Wermer MJH, Terwindt GM. Women with migraine have an increased risk of cardiovascular disease; what are the consequences for the clinical management of young patients? *Ned Tijdschr Geneeskd*. 2017;161:D1143

**Linstra KM**, Perenboom MJL, van Zwet EW, van Welie C, Fronczek R, Tannemaat MR, Wermer MJH, MaassenVanDenBrink A, Terwindt GM. Cold extremities in migraine: A marker for vascular dysfunction in women. *Eur J Neurol*. 2020 Jul;27(7):1197-1200

**Linstra KM**, Ibrahim K, van Casteren DS, Wermer MJH, Terwindt GM, MaassenVanDenBrink A. Pain perception in women with menstrually related migraine. *Cephalalgia*. 2021 Mar;41(3):417-421

**Linstra KM**, Van Os HJ, Ruigrok YM, Nederkoorn PJ, Van Dijk EJ, Kappelle LJ, Koudstaal PJ, MaassenVanDenBrink AH, Terwindt GM, Wermer MJH. Sex differences in risk profile, stroke cause and outcome in ischemic stroke patients with and without migraine. *Front. Neurosci*. 2021;

Al-Hassany L, **Linstra KM**, Meun C, Van den Berg J, Boersma EH, Danser AHJ, Fauser BCJ, Laven JS, Wermer MJH, Terwindt GM, MaassenVanDenBrink AH, on behalf of the CREW consortium. Decreased role of neuropeptides in the microvascular function in migraine patients with polycystic ovary syndrome. *Submitted*

Van Os HJ, **Linstra KM**, Ferrari MD, Lijfering WM, Dekkers OM, Helmerhorst FM, Terwindt GM, MaassenVanDenBrink A, Kittner SJ, Wermer MJH. Ischemic stroke risk in women with migraine and hormonal contraception: new case-control study and extended meta-analysis. *Submitted*

Zoet GA, **Linstra KM**, Bernsen MLE, Koster MPH, van der Schaar IC, Kappelle LJ, van Rijn BB, Franx A, Wermer MJH, Velthuis BK; DUST investigators. Stroke after pregnancy disorders. *Eur J Obstet Gynecol Reprod Biol*. 2017;215:264-266

Al-Hassany L, **Linstra KM**, Terwindt GM, MaassenVanDenBrink a. Cardiovascular Risk of Migraine in Men and Women. *Gender and Migraine, Headache*. 2019;2:17-29

Benschop H, Brouwers L, Zoet GA, Meun C, Boersma H, Budde RPJ, Fauser BCJM, De Groot CJM, Van der Schouw YT, Maas AHEM, Velthuis BK, **Linstra KM**, Kavousi M, Duvekot JJ, Franx A, Steegers E, Van Rijn BB, Roeters van Lennep JE. Early onset of coronary artery calcification in women with previous preeclampsia. *Circulation: Cardiovascular Imaging*

## CURRICULUM VITAE

Katie Linstra was born on the 13th of February, 1987 in Gouda, the Netherlands. She attended secondary school at the bilingual department of the “Wolfert van Borselen” in Rotterdam. In 2005 she was accepted at University College Utrecht, where she graduated cum laude with a premedical science major. During her bachelor, she participated in an exchange semester at the National University of Singapore in 2007, following courses in Pharmacology, Nanotechnology and Health psychology. Her bachelor thesis research concerned painful diabetic neuropathy. In 2008 she started a master in medicine at the Selective Utrecht Medical Masters (SUMMA) programme at the University Medical Centre in Utrecht. As part of her research traineeship, she investigated a new method of spinal cord stimulation for chronic pain at the department of Neurosurgery, Anaesthesiology and Medical Technology. After obtaining her medical degree in 2012, she worked as a resident (ANIOS) at the Department of Neurology of the Tergooi ziekenhuis in Blaricum. In 2014, she started her PhD research at the Neurology department of the Leiden University Medical Center and at the department of Internal Medicine, Division of Vascular Medicine and Pharmacology at the Erasmus Medical Centre in Rotterdam, under the guidance of prof.dr. M.J.H. Wermer, prof. dr. A. MaassenvandenBrink and prof. dr. G. M. Terwindt. Katie is currently working at a.s.r. as medical advisor.

## DANKWOORD

Dit proefschrift is het resultaat van een behoorlijke reis, die ik heb kunnen afleggen door de bijdrage en steun van velen.

Als eerst wil ik alle deelnemers aan de CREW studie bedanken voor hun vrijwillige inzet. Ik heb veel van jullie mogen leren, niet in de laatste plaats hoe veerkrachtig een mens kan zijn na medische tegenspoed.

Veel dank gaat uit naar mijn promotor en co-promotores, prof. dr. Marieke Wermer, prof. dr. Antoinette Maassen van den Brink en prof. dr. Gisela Terwindt. Het is een bijzonder voorrecht geweest om door jullie te worden begeleid, als drietal inspirerende vrouwen met hart voor de wetenschap.

Marieke, dank voor je niet aflatende vertrouwen en relativeringsvermogen. Je rust en realiteitszin hebben mij de eindstreep doen halen. Gisela, met bewonderingswaardige energie en als betrokken hoeder van de hoofdpijnonderzoeksgroep heb ik veel van je mogen leren. Antoinette, als anker in Rotterdam, je diepgaande vragen hielden me scherp, je steun in woelige tijden vergeet ik niet.

Ik heb het geluk gehad onderdeel te mogen zijn van maar liefst drie onderzoeksgroepen gedurende mijn tijd als PhD. Het multidisciplinaire CREW consortium, de hoofdpijnonderzoeksgroep in het LUMC en de vasculaire geneeskunde onderzoeksgroep in het EMC.

Michel en Jan, het was bijzonder om tussen jullie afdelingen te mogen laveren. Hoewel ik slechts indirect onder jullie hoede viel heb ik kunnen rekenen op jullie betrokkenheid en interesse.

Eric, Bart en alle CREW leaders; ik heb het als enorm leerzaam ervaren om binnen de dynamiek van een multidisciplinair consortium te opereren. Mark, Birgitta, Jeanine, Joop en Aad, bedankt dat ik bij jullie mocht aankloppen met al mijn ideeën en vragen tijdens de opzet van de CREW studie. Natuurlijk dank aan de CREW-crew: Gerbrand, Giske, Luuk, Sara, Veerle, Marlise en Laura Brouwer voor het delen van jullie enthousiasme. Cindy en Laura, onze koffietjes waren momenten van bezinning en harten onder de riem.

Kayi en Khatera, samen “K3”, in het Erasmus hebben jullie mij veel geholpen aan het begin van mijn avontuur in het hoofdpijnonderzoek. Dank ook aan Langeza, Stephanie, Linda en alle andere collega's voor de goede sfeer en fijne samenwerking.

Van mijn onderzoeksgenoten in het LUMC wil ik in het bijzonder mijn lieve kamergenoten bedanken, Patty, Daphne en Irene, voor de steun die zij zijn geweest. Natuurlijk ook Thijs, Dennis, Judith, Gerrit, Robin, Ilse, Nadine, Joris, Simone, Iris, Inge en Inge. Dank ook aan Hine, Nelleke en Bart, voor het overnemen en doorzetten van gedeeltes van het CREW onderzoek.

Dank Inge en Jordi, die mij in het LUMC met veel geduld hebben ingewijd in de magische wereld van de MRI.

Zonder de hulp van de studenten die voor het CREW onderzoek hebben gewerkt, waren mijn onderzoeksdagen nooit zo efficiënt en gezellig verlopen. Dank Sofie, Nienke, Rein, Ivo en Victor.

Paranimfen Ischa en Laura, mijn oudste en mijn nieuwste vriendin. Thee, taart, yoga, even mopperen op alles of juist carrièrepaden smeden als vrouwen in de wetenschap. Ik heb het allemaal met jullie mogen delen en daar ben ik dankbaar voor, net als dat ik jullie aan mijn zij mag hebben tijdens de verdediging.

Mijn chicas, Loes, Lottie, Fre en Ott, mijn rotsvaste lievelingen. Ik ben eigenlijk altijd trots op ons.

Mijn lieve oelwappers Emma, Iertje en Nien. Hoe kostbaar zijn vrienden die ruimte hebben om naar je te luisteren én als het nodig is over alles heen kunnen bruisen met liters goede energie?

Lieve pap en mam, jullie hebben mij altijd onvoorwaardelijk gesteund en met alle liefde gestimuleerd om uitdaging te blijven zoeken. Dat is de voedingsbodem geweest voor mijn nieuwsgierigheid en creativiteit. Lieve zus en broer, Saar en Max, wat ben ik blij dat wij er voor elkaar zijn en dat we weinig woorden nodig hebben om elkaar te begrijpen.

Als laatst bedank ik jou, mijn lieve Cas. Dat jij staat naast me staat, is alles wat ik nodig heb.







